Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.4K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

73
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
73

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Clinical phenotyping of asthma patients with elevated sputum eosinophils and low blood eosinophils: a post-hoc analysis of the multicentre ATLANTIS cohort.

EBioMedicine·2026
Same author

How artificial intelligence could improve the diagnosis and management of COPD: a perspective from GOLD.

American journal of respiratory and critical care medicine·2026
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same author

Mucus Plug Formation is Associated with Eosinophilic Activation in Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2026
Same author

Airway Mucus Plugs in Asthma and COPD: Pathobiology, Imaging, and Implications for Clinical Trials.

American journal of respiratory and critical care medicine·2026

Video Experimental Relacionado

Updated: May 7, 2026

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.5K

Eficacia y seguridad de benralizumab en pacientes con asma grave no controlada con dosis altas de corticosteroides

Eugene R Bleecker1, J Mark FitzGerald2, Pascal Chanez3

  • 1Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Lancet (London, England)
|September 10, 2016
PubMed
Resumen
Este resumen es generado por máquina.

Benralizumab redujo significativamente las exacerbaciones del asma y mejoró la función pulmonar en pacientes con asma grave, no controlada y con recuentos altos de eosinófilos. Este anticuerpo monoclonal ofrece una nueva opción de tratamiento para este grupo de pacientes.

Más Videos Relacionados

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Videos de Experimentos Relacionados

Last Updated: May 7, 2026

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

23.5K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.6K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

Área de la Ciencia:

  • Pulmonología
  • Inmunología
  • Farmacología

Sus antecedentes:

  • La eosinofilia está relacionada con un aumento de la gravedad del asma, una reducción de la función pulmonar y exacerbaciones más frecuentes.
  • El asma grave y no controlada con eosinofilia plantea un desafío clínico significativo.
  • Benralizumab se dirige al receptor α de la interleucina-5, agotando los eosinófilos a través de la citotoxicidad celular dependiente de los anticuerpos.

Objetivo del estudio:

  • Evaluar la seguridad y eficacia de benralizumab en pacientes con asma severa y no controlada y eosinofilia.
  • Evaluar el impacto de benralizumab en las tasas de exacerbación, la función pulmonar y los síntomas del asma.

Principales métodos:

  • Un estudio aleatorizado, doble ciego, controlado con placebo de fase 3 en el que participaron 1205 pacientes con asma severa y no controlada.
  • Los pacientes recibieron benralizumab (30 mg Q4W o Q8W) o placebo durante 48 semanas como tratamiento complementario.
  • El criterio de valoración primario: proporción de la tasa de exacerbaciones anuales; el criterio de valoración secundario: VEF1 y puntuación de los síntomas de asma, estratificado por el recuento de eosinófilos (≥300 células/μL).

Principales resultados:

  • Benralizumab redujo significativamente la tasa anual de exacerbaciones de asma en un 45-51% en comparación con el placebo (p< 0, 0001).
  • Tanto los regímenes Q4W como Q8W de benralizumab mejoraron el FEV1 prebroncodilatador en la semana 48.
  • El régimen Q8W mejoró los síntomas del asma, mientras que el régimen Q4W no mostró una mejoría significativa en comparación con el placebo.

Conclusiones:

  • Benralizumab demuestra una eficacia significativa y un perfil de seguridad favorable en pacientes con asma grave y eosinofilia.
  • Los hallazgos apoyan a benralizumab como una opción de tratamiento eficaz para esta población específica de pacientes.
  • Benralizumab reduce eficazmente las exacerbaciones y mejora la función pulmonar en el asma eosinofílica grave.